It’s a big year in the world of Alzheimer’s research. In early July, the FDA approved the Alzheimer’s drug Leqembi, which is the first drug to show clinical evidence of slowing down cognitive decline.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first blood test aiding Alzheimer's diagnosis by detecting amyloid plaques, offering a less invasive alternative to PET scans. The test ...

A blood test can tell which people may benefit most from anti-amyloid drugs — which could ease costs and prevent individuals from unneeded medicines, according to a new study published Dec. 4 in JAMA ...

Findings suggest the test can reduce the need for PET imaging in some patients with mild cognitive decline to enable therapeutic focus on non-Alzheimer's disease causes, broadening access to quality ...

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information and tools designed to improve your well-being. A combined blood test for ...

New criteria could lead to a diagnosis on the basis of a simple blood test, even in the absence of obvious symptoms. By Paula Span Determining whether someone has Alzheimer’s disease usually requires ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related to Alzheimer's disease in individuals with mild cognitive impairment (MCI) ...

Fluid tests for Alzheimer’s disease are hurtling toward widespread use. At the Clinical Trials on Alzheimer’s Disease conference, held November 29 through December 2 in San Francisco, several groups ...

A link between abnormal blood levels of amyloid -- a protein associated with Alzheimer's disease -- and subtle changes in brain microstructures on a type of MRI could lead to a new way to detect ...

Testing a person’s blood for a type of protein called phosphorylated tau, or p-tau, could be used to screen for Alzheimer’s disease with “high accuracy,” even before symptoms begin to show, a new ...

Findings showed 91.7% of patients with positive results using Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test had amyloid plaques based on PET scan or CSF test results. The Food and Drug ...

Plasma phosphorylated tau 217 (p-tau217) outperformed p-tau181, p-tau231, and other blood-based biomarkers to identify which patients might benefit most from anti-amyloid Alzheimer's drugs, a cohort ...